This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
| ISBN: | 9783319858500 |
| Publication date: | 2nd August 2018 |
| Author: | Augusto Villanueva |
| Publisher: | Springer an imprint of Springer International Publishing |
| Format: | Paperback |
| Pagination: | 147 pages |
| Series: | Resistance to Targeted Anti-Cancer Therapeutics |
| Genres: |
Oncology |